A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Summary

The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women

Timeline

Start

2017-07-11

Primary completion

2017-07-14

Completion

2017-07-14

Outcome

Outcome not reported

Stopped: “Study was canceled due to instability of the PreF antigen during manufacturing. No safety concern has been identified in past or ongoing studies.”

Drugs

Indications